Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $28.2552W HIGH $60.08
Volume
100.83 K
Value Traded
5.71 M
Short % Float
4.94%
Days to Cover
4.3
+0.15%Week
+8.73%1 Month
+6.96%3 Month
-29.2%6 Month
+14.49%5 Year
+101.58%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.58 B
EPS (TTM)
2.46
P/E Ratio
15.82
Ent. Value
1.50 B
Total Shares
40.60 M
Float Shares
20.92 M
Insiders
48.48%
Institutions
52.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PAHC Catalyst Timeline
Dated clinical, regulatory and corporate events for Phibro Animal Health Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Phibro Animal Health Corporation
111Total events
3Upcoming
19Tier-1 (high impact)
2005 to 2026Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Phibro management to host conference call and webcast on Q4/FY2026 results
◆Management ChangeCorporate
Jack Bendheim to become Executive Chairman; Daniel Bendheim named CEO and President effective July 1, 2026
▲Quarterly UpdateCorporate
FY2026 guidance raised: net sales $1.45B-$1.50B, adjusted EBITDA $245M-$255M
●Oral PresentationPresentation
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
●Oral PresentationPresentation
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference
▲Partnership / LicenseCorporate
Phibro Animal Health Corporation launches VERRATAIN Verified Sustainability Solutions through strategic VAXA Technologies partnership
▲Product LaunchPost-Market
Launch of Sustainable Solutions Platform including VERRATAIN Verified Sustainability Solutions
◆Other Regulator MilestoneEx-US Regulatory
Regulatory framework change in Brazil for antimicrobials
antimicrobialssource ↗
◆Other Regulator MilestoneEx-US Regulatory
Regulatory development in Brazil affecting certain antimicrobial products
▲Product LaunchRestorisPost-Market
National launch of Restoris dental gel for dogs with periodontal disease
canine periodontal diseasesource ↗
◆Quarterly UpdateCorporate
Q1 earnings call to provide additional financial details on acquisition
▲Partnership / LicenseCorporate
Closed acquisition of Zoetis' Medicated Feed Additive portfolio
▲AcquisitionCorporate
Phibro completes acquisition of Zoetis' medicated feed additive product portfolio and certain water-soluble products
▲Partnership / LicenseCorporate
Signed agreement to acquire Zoetis' Medicated Feed Additive portfolio and certain water soluble products
◆AcquisitionCorporate
Phibro Animal Health to acquire Zoetis' medicated feed additive portfolio
◆Management ChangeCorporate
Richard G. Johnson to assume interim CFO role effective September 30, 2023
●Quarterly UpdateCorporate
Revised FY2023 guidance for Net income, Diluted EPS, Adjusted net income, Adjusted diluted EPS, Adjusted effective tax rate
▲Product LaunchPost-Market
Opened new autogenous vaccine facility in Brazil and launched new commercial poultry vaccines in Latin America
▲Pipeline PrioritizationCorporate
Added gene-therapy opportunity to companion animal development pipeline
companion animalsource ↗
▲Quarterly UpdateCorporate
Phibro Animal Health reports Q2 FY2022 results and raises full-year net sales guidance
●Quarterly UpdateCorporate
Phibro Animal Health reports Q4 and fiscal year 2021 financial results
Past FDA Catalysts and PDUFA Decisions
How PAHC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Phibro Animal Health Corporation is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PAHC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bendheim Daniel MDirector, Officer (President and CEO) | Grant/Award | 300,000 300,000 held | $0.00 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PAHC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0.4 % (100 %) | 5.36 M | 238.18 K | 0.5% ( 1.18 K) |
PAHC Institutional Ownership Trends
PAHC Short Interest
Shares sold short, counted twice a month.
4.94%
Short % of Float
of tradable shares sold short
1.0M
Shares Sold Short
+1.1% vs prior count
4.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
239.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PAHC ranks across every disease it competes in
Competitive Position is a premium feature
See how PAHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPAHC News
PAHC▲ +2.6%today
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
Phibro Animal Health Corporation plans to announce its first quarter financial results on November 4, 2026. A conference call and webcast will follow on November 5, 2026, at 9:00 AM Eastern Time. Interested investors can access the call and presentation slides through the company's investor website.
Read more →PAHCPhibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference
Phibro Animal Health Corporation will participate in the Morgan Stanley Annual Global Healthcare Conference on September 15, 2026. The event will feature presentations from key executives, including the CEO and CFO, aimed at financial analysts and investors. This engagement underscores the company's commitment to transparency and investor relations.
Read more →PAHCPhibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Phibro Animal Health Corporation reported a 5% increase in net sales for the fourth quarter, totaling $396.7 million. The company's net income also rose to $21.7 million, reflecting a positive financial performance compared to the previous year. Additionally, Phibro provided optimistic financial guidance for the fiscal year ending June 30, 2027.
Read more →PAHCPhibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
Phibro Animal Health Corporation will announce its fourth quarter and fiscal year 2026 financial results on August 26, 2026. A conference call and webcast will follow on August 27, 2026, at 9:00 AM Eastern Time. Interested parties can access the call and presentation slides via the company's investor website.
Read more →PAHCPhibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation's Board of Directors has announced a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. This dividend is set to be paid on September 23, 2026, to shareholders on record as of September 2, 2026. The announcement highlights the company's ongoing commitment to shareholder returns.
Read more →PAHCPhibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
Phibro Animal Health Corporation is set to participate in the Stifel Jaws & Paws Conference. The event will provide a platform for the company to engage with investors and discuss its strategies and outlook. Further details about the conference and the company's participation were not disclosed in the article.
Read more →PAHC▼ -26.2%on this news· ran to -37% by day 3
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference
Phibro Animal Health Corporation is set to participate in the upcoming Bank of America Securities Health Care Conference. This event will provide an opportunity for the company to engage with investors and discuss its strategies and performance. Details regarding the date and format of the conference have not been specified.
Read more →PAHCPhibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation has reported its third-quarter results and provided updates on its financial guidance. The report includes key financial metrics and insights into the company's performance during the quarter. However, specific details regarding revenue or profit changes were not disclosed in the article.
Read more →PAHCPhibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership
Phibro Animal Health Corporation has launched a sustainable solutions platform named VERRATAIN™. This initiative is a result of a strategic partnership with VAXA Technologies, aimed at promoting verified sustainability solutions across the company. The details of the platform and its expected impact on the market were not elaborated in the article.
Read more →PAHCPhibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
Phibro Animal Health Corporation will announce its third quarter financial results on May 6, 2026. A conference call and webcast are scheduled for May 7, 2026, at 9:00 AM ET, allowing interested parties to engage with the company's management. A replay of the webcast will be available shortly after the live event.
Read more →PAHCPhibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials
Phibro Animal Health Corporation has announced a change in the regulatory framework for antimicrobials in Brazil. This development may impact the market dynamics for animal health products. Further details on the implications of this change have not been provided in the article.
Read more →PAHCPhibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation reported robust financial results for its second quarter ending December 31, 2025, showcasing a 21% increase in net sales to $373.9 million and a substantial rise in net income to $27.5 million. The adjusted earnings also saw a notable increase, indicating strong operational performance and effective management. The company has raised its fiscal year 2026 guidance, reflecting confidence in continued growth driven by an integrated MFA portfolio and sustained demand in their nutritional and vaccine products. Overall, the results depict a positive trajectory for Phibro amidst a challenging global environment.
Read more →PAHCPhibro Animal Health Corporation Announces Leadership Transition - Jack Bendheim to assume the role of Executive Chairman; Daniel Bendheim named Chief Executive Officer and President
Phibro Animal Health Corporation has announced a leadership transition where current CEO Jack Bendheim will become Executive Chairman and Daniel Bendheim will take over as CEO and President effective July 1, 2026. This change is seen as crucial for the company's ongoing growth and strategic direction. Jack Bendheim, who has been with the company since 1969 and has led it since 1988, expressed confidence in Dani's ability to lead as they continue to prioritize customer focus and innovation. The Board of Directors fully supports this transition.
Read more →PAHCPhibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation reported strong financial results for its first quarter ending September 30, 2025, with net sales rising 40% to $363.9 million and adjusted earnings per share doubling to $0.73. The growth was primarily driven by the Animal Health segment, which experienced a 55% increase in sales, buoyed by high demand for minerals, nutritional products, and vaccines. While the overall operational performance was strong, the Performance Products segment faced a decline in revenue. The company also updated its financial guidance, raising expectations for the fiscal year.
Read more →PAHCPhibro Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors
Phibro Animal Health Corporation has appointed Joyce J. Lee as a Class II director, effective immediately. This appointment fills a vacancy on the board and increases its size to nine directors, with six being independent. Ms. Lee has a strong background in animal health and has held executive positions at notable companies, contributing to her strategic and operational expertise. The company's CEO expressed optimism about her ability to drive value and enhance board effectiveness.
Read more →About Phibro Animal Health Corporation
HeadquartersGLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ, 07666
BIOPHARMAWATCH ELITE PLUS
Trade the next PAHC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime